Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Literature
1.
Seo K, Yang JH, Kim SC, Ku SK, Ki SH, Shin SM. 2013. The antioxidant effects of isorhamnetin contribute to inhibit COX-2 expression in response to inflammation: A potential role of HO-1. Inflammation. 2013 Dec 13, in press
2.
Yang, J.H., B.Y. Shin, J.Y. Han, M.G. Kim, J.E. Wi, Y.W. Kim, I.J. Cho, S.C. Kim, S.M. Shin, and S.H. Ki. 2014. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicology and Applied Pharmacology 274(2): 293–301.PubMedCrossRef
3.
Liu, W., S. Liu, P. Yao, L.G. Liu, and H. Qin. 2013. Potential molecular mechanisms of quercetin-induced heme oxygenase-1 in rat primary hepatocytes. Zhonghua Gan Zang Bing Za Zhi 21(11): 865–868.PubMed
4.
5.
6.
Chi, Y.S., and H.P. Kim. 2005. Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from Scutellaria radix. Prostaglandins, Leukotrienes, and Essential Fatty Acids 72(1): 59–66.PubMedCrossRef
7.
Pan, M.H., C.S. Lai, Y.J. Wang, and C.T. Ho. 2006. Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice. Biochemical Pharmacology 72(10): 1293–1303.PubMedCrossRef
8.
Kim, H.R., C.G. Park, and J.Y. Jung. 2014. Acacetin (5,7-dihydroxy-4′-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells. International Journal of Molecular Medicine 33(2): 317–324.PubMed
9.
O’Leary, K.A., S. de Pascual-Teresa, P.W. Needs, Y.P. Bao, N.M. O’Brien, and G. Williamson. 2004. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutation Research 551(1–2): 245–254. Erratum in: Mutat Res. 2013 Sep;749(1–2):92.PubMedCrossRef
10.
Jones, D.J., J.H. Lamb, R.D. Verschoyle, L.M. Howells, M. Butterworth, C.K. Lim, D. Ferry, P.B. Farmer, and A.J. Gescher. 2004. Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. British Journal of Cancer 91(6): 1213–1219.PubMedCentralPubMed
11.
Laube, M., T. Kniess, and J. Pietzsch. 2013. Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity–a critical update. Molecules 18(6): 6311–6355.PubMedCrossRef
12.
Wang, Y.C., and K.M. Huang. 2013. In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells. Food and Chemical Toxicology 53: 376–383.PubMedCrossRef
13.
Park, C.M., and Y.S. Song. 2013. Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-κB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells. Nutrition Research and Practice 7(6): 423–429.PubMedCentralPubMedCrossRef
14.
Ha, S.K., E. Moon, and S.Y. Kim. 2010. Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-κB and JNK activations in microglia cells. Neuroscience Letters 485(3): 143–147.PubMedCrossRef
15.
Pandith, H., X. Zhang, S. Thongpraditchote, Y. Wongkrajang, W. Gritsanapan, and S.J. Baek. 2013. Effect of Siam weed extract and its bioactive component scutellarein tetramethyl ether on anti-inflammatory activity through NF-κB pathway. Journal of Ethnopharmacology 147(2): 434–441.PubMedCrossRef
16.
Yang, J.H., S.C. Kim, B.Y. Shin, S.H. Jin, M.J. Jo, K.H. Jegal, Y.W. Kim, J.R. Lee, S.K. Ku, I.J. Cho, and S.H. Ki. 2013. O-methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-κB activation. Food and Chemical Toxicology 59: 362–372.PubMedCrossRef
17.
Kim, T.H., S.K. Ku, and J.S. Bae. 2013. Anti-inflammatory activities of isorhamnetin-3-O-galactoside against HMGB1-induced inflammatory responses in both HUVECs and CLP-induced septic mice. Journal of Cellular Biochemistry 114(2): 336–345.PubMedCrossRef
18.
Wang, G., D. Han, Y. Zhang, X. Xie, Y. Wu, S. Li, and M. Li. 2013. A novel hypothesis: Up-regulation of HO-1 by activation of PPARγ inhibits HMGB1-RAGE signaling pathway and ameliorates the development of ALI/ARDS. Journal of Thoracic Disease 5(5): 706–710.
19.
Christensen, K.B., R.K. Petersen, K. Kristiansen, and L.P. Christensen. 2010. Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma. Phytotherapy Research 24(Suppl 2): S129–S132.PubMedCrossRef
20.
Ramachandran, L., K.A. Manu, M.K. Shanmugam, F. Li, K.S. Siveen, S. Vali, S. Kapoor, T. Abbasi, R. Surana, D.T. Smoot, H. Ashktorab, P. Tan, K.S. Ahn, C.W. Yap, A.P. Kumar, and G. Sethi. 2012. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. Journal of Biological Chemistry 287(45): 38028–38040.PubMedCentralPubMedCrossRef
Metadata
Title
Anti-Inflammatory Action of Isorhamnetin
Author
Salvatore Chirumbolo
Publication date
01-08-2014
Publisher
Springer US
Published in
Inflammation / Issue 4/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9846-9

Other articles of this Issue 4/2014

Inflammation 4/2014 Go to the issue

OriginalPaper

Assessment of Inflammatory Biomarkers and Oxidative Stress in Pulmonary Thromboembolism: Follow-up Results

OriginalPaper

Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint Inflammation in Mice

OriginalPaper

Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia

OriginalPaper

Polymyxin B Protects Against Hepatic Ischemia/Reperfusion Injury in a Rat Model of Obstructive Jaundice

OriginalPaper

Anti-inflammatory Effects of Triptolide in LPS-Induced Acute Lung Injury in Mice

OriginalPaper

Association of Interleukin 1 Family with Systemic Sclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits